Skye Bioscience, Inc. (SKYE)
| Market Cap | 28.58M -54.6% |
| Revenue (ttm) | n/a |
| Net Income | -57.33M |
| EPS | -1.45 |
| Shares Out | 35.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 197,254 |
| Open | 0.8700 |
| Previous Close | 0.8712 |
| Day's Range | 0.8026 - 0.8700 |
| 52-Week Range | 0.5655 - 5.7500 |
| Beta | 3.02 |
| Analysts | Buy |
| Price Target | 7.71 (+847.64%) |
| Earnings Date | May 11, 2026 |
About SKYE
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in S... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for SKYE stock is "Buy." The 12-month stock price target is $7.71, which is an increase of 847.64% from the latest price.
News
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-...
Skye Bioscience price target lowered to $6 from $13 at Piper Sandler
Piper Sandler lowered the firm’s price target on Skye Bioscience (SKYE) to $6 from $13 and keeps an Overweight rating on the shares. The firm notes Skye ended Q1 2026…
Skye Bioscience reports Q1 EPS (32c), consensus (32c)
“Since our March update, execution has focused on turning CBeyond into a Phase 2b-ready development program,” said Punit Dhillon, President & CEO of Skye. “We have now initiated enrollment of…
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-...
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other m...
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study Topline safety and pharmacokinetic data expected in Q4 2026; an independen...
Skye Bioscience Earnings Call Transcript: Q4 2025
Nimacimab's CBeyond program showed strong additive weight loss and safety in combination with GLP-1s, with higher dose studies and subcutaneous delivery advancing toward Phase IIb. Cash runway extends through Q4 2026, and early APC platform data support future pipeline growth.
Skye Bioscience reports Q4 EPS (36c), consensus (31c)
Cash, cash equivalents, and short-term investments totaled $25.7M as of December 31, 2025. “All of the data generated and reported in the past year along with the incremental data highlighted…
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules that modul...
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other ...
Skye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab
Skye Bioscience (SKYE) announced interim 52-week data from the combination therapy arms in the extension phase of the Phase 2a CBeyond proof-of-concept study of nimacimab, its peripherally-restricted ...
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimac...
Skye Bioscience presents poster on efficacy of Nimacimab
Skye Bioscience (SKYE) presented a poster titled “Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a D...
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other me...
Skye Bioscience to Present Poster at Keystone Obesity Conference
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other me...
Skye Bioscience provides 2026 corporate outlook
“In 2025 we generated our Phase 2a clinical data, deepened our understanding of nimacimab’s exposure-response dynamics, and built the technical foundation required to test higher doses and prepare the...
Skye Provides 2026 Corporate Outlook
CBeyond TM Phase 2a 26-week extension data update and interim results expected Q1 2026. CBeyond Phase 2a Data Monitoring Committee (DMC) meeting on December 14, 2025, continued to demonstrate favorabl...
Skye Bioscience, Halozyme enter collaboration, license agreement
Halozyme Therapeutics (HALO) and Skye Bioscience (SKYE) announced the companies entered into a non-exclusive global collaboration and license agreement in December 2025. Under the collaboration, Skye ...
Halozyme, Skye Bioscience announce global collaboration, license agreement
Halozyme Therapeutics (HALO) and Skye Bioscience (SKYE) announced the companies entered into a non-exclusive global collaboration and license agreement in December 2025. Under the collaboration, Skye ...
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: H...
Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.
SAN DIEGO--(BUSINESS WIRE)---- $SKYE #Biopharmaceutical--Robbins LLP: Company: Skye Bioscience, Inc. (NYSE: SKYE) is a clinical stage biopharmaceutical company that focuses on developing molecules tha...
Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation
SAN DIEGO , Dec. 8, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announces that a deadline is coming up in the lawsuit for certain investors in shares of Skye Bioscience, Inc. (NASDAQ: SKYE)...
Skye Bioscience Transcript: Piper Sandler 37th Annual Healthcare Conference
A peripherally restricted CB1 antibody shows promise for obesity, with strong safety and synergistic weight loss when combined with incretins. Ongoing studies focus on higher dosing, durability, and optimal combinations, supported by robust preclinical and clinical data.
Skye Bioscience Transcript: Evercore ISI 8th Annual HealthCONx Conference
Phase II data for a peripherally restricted CB1 antibody showed suboptimal monotherapy efficacy but strong synergy with semaglutide, leading to 30% greater weight loss at 26 weeks. Higher dosing and improved formulations are planned, with key 52-week extension data expected in Q1.
Skye Bioscience to Participate in Upcoming Investment Conferences
San Diego, California--(Newsfile Corp. - November 24, 2025) - Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for ob...